Catherine Hefner
Family · Statesville, NCNPI 1336870187
Payments from drug & device makers
Across 354 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$989
- Xeris Pharmaceuticals, Inc.$498
- Bayer$286
- Recordati_rare_diseases_inc.$193
- AstraZeneca$192
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,89098%
- Other$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 103 | $1,263 |
| Lilly USA, LLC | 59 | $989 |
| Xeris Pharmaceuticals, Inc. | 29 | $498 |
| Bayer | 19 | $286 |
| Recordati_rare_diseases_inc. | 9 | $193 |
| AstraZeneca | 11 | $192 |
| Boehringer Ingelheim | 11 | $184 |
| Amphastar Pharmaceuticals, Inc. | 7 | $161 |
| Amneal Pharmaceuticals LLC | 9 | $155 |
| Corcept Therapeutics | 9 | $153 |
| Tandem Diabetes Care, Inc. | 7 | $123 |
| BETA Bionics, Inc. | 5 | $115 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Madrigal Pharmaceuticals | 4 | $112 |
| Amgen | 6 | $110 |
| Mannkind Corporation | 6 | $109 |
| Abbott | 2 | $100 |
| Tolmar, Inc. | 5 | $90 |
| Medtronic | 4 | $90 |
| Cequr Corporation | 3 | $86 |
| Ascendis Pharma Endocrinology Inc | 3 | $80 |
| IBSA Pharma Inc. | 3 | $70 |
| Nevro Corp. | 4 | $70 |
| Abiomed | 3 | $67 |
| Chiesi USA, Inc. | 2 | $57 |
| Ascensia Diabetes Care US Inc. | 3 | $54 |
| Pfizer | 2 | $49 |
| AbbVie | 3 | $48 |
| Radius Health, Inc. | 2 | $48 |
| Rhythm Pharmaceuticals, Inc. | 2 | $48 |
| GSK | 2 | $41 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Dexcom, Inc. | 1 | $35 |
| Veryan Medical Incorporated | 1 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $28 |
| Insulet Corporation | 1 | $23 |
| Lifescan, Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
How this compares
$5,990 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $348,854 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $125,475 |
| Tresiba Flextouch U-100Insulin Degludec | 142 | $99,268 |
| JardianceEmpagliflozin | 110 | $94,875 |
| MounjaroTirzepatide | 67 | $75,263 |
| TrulicityDulaglutide | 43 | $53,040 |
| RybelsusSemaglutide | 41 | $45,795 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $39,385 |
| FarxigaDapagliflozin Propanediol | 30 | $36,173 |
| Humalog Kwikpen U-100Insulin Lispro | 120 | $32,817 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 187 | $28,388 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $28,124 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $28,001 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $24,917 |
| Novolog FlexpenInsulin Aspart | 69 | $18,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,263 | $400,046338 claims |
| Lilly USA, LLCMounjaro, Trulicity | $989 | $128,303110 claims |
| Boehringer IngelheimJardiance | $184 | $94,875110 claims |
| AstraZenecaFarxiga | $192 | $36,17330 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $114 | $28,00122 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $155 | $23141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Statesville
- Kimberly WoodsStatesville$62K
- Deborah DaywaltStatesville$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.